Friends of AHRQ Hold First Meeting of New Year

Dr Carolyn Clancy, Director of AHRQ, presented a briefing at the meeting which included a discussion of new priority areas for comparative effectiveness research (CER), several of which had behavioral or psychological foci.
On February 25, Science GRO attended the Friends of the Agency for Health Research and Quality (AHRQ) meeting to hear a briefing by Dr Carolyn Clancy, Director of AHRQ. Dr. Clancy’s presentation included a discussion of new priority areas for comparative effectiveness research (CER), several of which had behavioral or psychological foci including: depression and other mental disorders; developmental delays, attention deficit hyperactivity disorder and autism; and substance abuse. AHRQ fared well when the American Recovery and Reinvestment Act (the stimulus bill) was signed into law, netting $300 million for CER.  Additionally, the Institute of Medicine (IoM) is conducting a study to help identify further CER research priorities for the $400 million allocated to the Secretary of Health and Human Services for CER.  As part of that effort, the IoM is requesting public comment.  On March 20, APA President James Bray was asked to give a statement presenting APA’s priorities on this topic.